{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T12:26:25Z","timestamp":1707740785687},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T00:00:00Z","timestamp":1434931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Front. Med."],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s11684-015-0400-4","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T06:42:01Z","timestamp":1434955321000},"page":"304-311","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase"],"prefix":"10.1007","volume":"9","author":[{"given":"Lanping","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,22]]},"reference":[{"issue":"17","key":"400_CR1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340(17): 1330\u20131340","journal-title":"N Engl J Med"},{"issue":"15","key":"400_CR2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003; 349(15): 1451\u20131464","journal-title":"N Engl J Med"},{"issue":"4","key":"400_CR3","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91(4): 513\u2013521","journal-title":"Haematologica"},{"key":"400_CR4","unstructured":"National Marrow Donor Program. Disease and transplant outcome data, NMDP-facilitated transplant outcomes. Available from: http:\/\/www.marrow.org\/MEDICAL\/diseaseoutcomedata.html . Accessed July 7, 2010"},{"issue":"10","key":"400_CR5","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"S Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, M\u00fcller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R; German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115(10): 1880\u20131885","journal-title":"Blood"},{"issue":"11","key":"400_CR6","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","volume":"117","author":"Q Jiang","year":"2011","unstructured":"Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Qin YZ, Liu YR, Lai YY, Huang XJ. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011; 117(11): 3032\u20133040","journal-title":"Blood"},{"key":"400_CR7","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines): chronic myelogenous leukemia","author":"National Comprehensive Cancer Network.","year":"2014","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines): chronic myelogenous leukemia. Version 2. 2014. www.nccn.org"},{"key":"400_CR8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P Coutre Le","year":"2008","unstructured":"Le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O\u2019Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H. Nilotinib (formly AMN 107), a highly selective BCR-ABL tyosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic mylogenous leukemia. Blood 2008; 111: 1834\u20131839","journal-title":"Blood"},{"issue":"6","key":"400_CR9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","volume":"26","author":"PD Coutre Le","year":"2012","unstructured":"Le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012; 26(6): 1189\u20131194","journal-title":"Leukemia"},{"issue":"10","key":"400_CR10","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or \u2014intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109(10): 4143\u20134150","journal-title":"Blood"},{"issue":"21","key":"400_CR11","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","volume":"27","author":"JF Apperley","year":"2009","unstructured":"Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J, Stone RM. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 2009; 27(21): 3472\u20133479","journal-title":"J Clin Oncol"},{"issue":"8","key":"400_CR12","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","volume":"107","author":"DP Lu","year":"2006","unstructured":"Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, Xu LP, Zhang YC, Ren HY, Li D, Liu KY. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLAidentical sibling transplantation. Blood 2006; 107(8): 3065\u20133073","journal-title":"Blood"},{"issue":"4","key":"400_CR13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","volume":"38","author":"XJ Huang","year":"2006","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Wang JZ, Gao ZY, Zhang YC, Jiang Q, Shi HX, Lu DP. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38(4): 291\u2013297","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"400_CR14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bbmt.2008.11.025","volume":"15","author":"XJ Huang","year":"2009","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu DP. Treatment of acute leukemia with unmanipulated HLA-mismatched\/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15(2): 257\u2013265","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"400_CR15","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1158\/1078-0432.CCR-09-0691","volume":"15","author":"XJ Huang","year":"2009","unstructured":"Huang XJ, Xu LP, Liu KY, Liu DH, Wang Yu, Chen Huan, Chen YH, Han Wei, Wang JZ, Chen Yao, Zhang XH, Shi HX, Wang FR, Tang FF. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009; 15(14): 4777\u20134783","journal-title":"Clin Cancer Res"},{"issue":"6","key":"400_CR16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Chen Y, Yan CH, Huo MR, Li D, Huang XJ. Who is the best donor for a related HLA haplotypemismatched transplant? Blood 2014; 124(6): 843\u2013850","journal-title":"Blood"},{"issue":"6","key":"400_CR17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/07853890801908903","volume":"40","author":"XJ Huang","year":"2008","unstructured":"Huang XJ, Xu LP, Liu KY, Liu DH, Chen H, Han W, Chen YH, Wang JZ, Chen Yao, Zhang XH, Shi HX, Lu DP. HLA-mismatched\/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008; 40(6): 444\u2013455","journal-title":"Ann Med"},{"issue":"4","key":"400_CR18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1751-553X.2007.00962.x","volume":"30","author":"YZ Qin","year":"2008","unstructured":"Qin YZ, Liu YR, Zhu HH, Li JL, Ruan GR, Zhang Y, Jiang Q, Jiang H, Li LD, Chang Y, Huang XJ, Chen SS. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. Int J Lab Hematol 2008; 30(4): 317\u2013323","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"400_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-010-1039-5","volume":"90","author":"Y Qin","year":"2011","unstructured":"Qin Y, Chen S, Jiang B, Jiang Q, Jiang H, Li J, Li L, Lai Y, Liu Y, Huang X. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol 2011; 90(1): 47\u201352","journal-title":"Ann Hematol"},{"issue":"5","key":"400_CR20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbmt.2010.07.023","volume":"17","author":"XJ Huang","year":"2011","unstructured":"Huang XJ, Xu LP, Liu KY, Liu DH, Chen H, Liu YR, Chen YH, Han W, Wang Y. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant 2011; 17(5): 649\u2013656","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"400_CR21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3324\/haematol.10570","volume":"92","author":"XJ Huang","year":"2007","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched\/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92(3): 414\u2013417","journal-title":"Haematologica"},{"issue":"10","key":"400_CR22","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"S Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, M\u00fcller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R; German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115(10): 1880\u20131885","journal-title":"Blood"},{"issue":"6","key":"400_CR23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/bmt.2011.194","volume":"47","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 2012; 47(6): 810\u2013816","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-015-0400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11684-015-0400-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-015-0400-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T13:38:13Z","timestamp":1566913093000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11684-015-0400-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,22]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1007\/s11684-015-0400-4","relation":{},"ISSN":["2095-0217","2095-0225"],"issn-type":[{"value":"2095-0217","type":"print"},{"value":"2095-0225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,22]]}}}